Article information
Full text is only aviable in PDF
References
[1]
J.G. Cleland, T. McDonagh, A.S. Rigby, et al.
The national heart failure audit for England and Wales 2008-2009.
Heart., 97 (2011), pp. 876-886
[2]
National Heart Failure Audit. Report for 2009/10. http://www. ic.nhs.uk/webfiles/Services/NCASP/audits%20and%20reports/NHS_National_Heart_FailureJVudit_09_INTERACTIVE.pdf.[accessed July 2011].
[3]
C.Y. Wong, S.I. Chaudhry, M.M. Desai, et al.
Trends in comorbid-ity, disability and polypharmacy in heart failure.
Am J Med., 124 (2011), pp. 136-143
[4]
J.H. Gurwitz, R.J. Goldberg.
Age-based exclusions from cardiovascular clinical trials: implications for elderly individuals (and for all of us): comment on “the persistent exclusion of older patients from ongoing clinical trials regarding heart failure”.
Arch Intern Med., 171 (2011), pp. 557-558
[5]
National Institute for Clinical Excellence. Chronic heart failure. Clinical guideline 108. London, UK: National Institute for Clinical Excellence; 2010.
[6]
A. Al-Mohammad, J. Mant.
The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines.
Heart., 97 (2011), pp. 411-416
[7]
K.E. Joynt, E.J. Orav, A.K. Jha.
The association between hospital volume and processes, outcomes and costs of care for congestive heart failure.
Ann Intern Med., 154 (2011), pp. 94-102
[8]
G.A. Macgowan, G. Parry, S. Schueler, et al.
The decline in heart transplantation in the UK.
Br Med J., 342 (2011), pp. d2483
[9]
N.R. Banner, R.S. Bonser, A.L. Clark, et al.
Guidelines for referral and assessment of adults for heart transplantation.
Heart., 97 (2011), pp. 1520-1527
[10]
R.K. Riezebos, E. Ronner, E. Ter Bals, et al.
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
Heart., 95 (2009), pp. 807-812
[11]
Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010:CD007228.
[12]
S.I. Chaudhry, J.A. Mattera, J.P. Curtis, et al.
Telemonitoring in patients with heart failure.
N Engl J Med., 363 (2010), pp. 2301-2309
[13]
F. Koehler, S. Winkler, M. Schieber, et al.
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study.
Circulation., 123 (2011), pp. 1873-1880
[14]
R.C. Bourge, W.T. Abraham, P.B. Adamson, et al.
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.
J Am Coll Cardiol., 51 (2008), pp. 1073-1079
[15]
U.C. Hoppe, M. Vanderheyden, H. Sievert, et al.
Chronic monitoring of pulmonary artery pressure in patients with severe heart failure: multicentre experience of the monitoring Pulmonary Artery Pressure by Implantable device Responding to Ultrasonic Signal (PAPIRUS) II study.
Heart., 95 (2009), pp. 1091-1097
[16]
W.T. Abraham, P.B. Adamson, R.C. Bourge, et al.
Wireless pul artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.
Lancet., 377 (2011), pp. 658-666
[17]
J. Ritzema, R. Troughton, I. Melton, et al.
Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure.
Circulation., 121 (2010), pp. 1086-1095
[18]
G.M. Felker, V. Hasselblad, A.F. Hernandez, et al.
Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
Am Heart J., 158 (2009), pp. 422-430
[19]
J.G. Lainchbury, R.W. Troughton, K.M. Strangman, et al.
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
J Am Coll Cardiol., 55 (2009), pp. 53-60
[20]
T.E. Owan, D.O. Hodge, R.M. Herges, et al.
Trends in prevalence and outcome of heart failure with preserved ejection fraction.
NEnglJMed., 355 (2006), pp. 251-259
[21]
R.S. Bhatia, J.V. Tu, D.S. Lee, et al.
Outcome of heart failure with preserved ejection fraction in a population-based study.
N Engl J Med., 355 (2006), pp. 260-269
[22]
D. Burkhoff, M.S. Maurer, M. Packer.
Heart failure with a normal ejection fraction: is it really a disorder of diastolic function?.
Circulation., 107 (2003), pp. 656-658
[23]
D.L. Brutsaert, G.W. De Keulenaer.
Diastolic heart failure: a myth.
Curr Opin Cardiol., 21 (2006), pp. 240-248
[24]
B.A. Borlaug, W.A. Jaber, S.R. Ommen, et al.
Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction.
Heart., 97 (2011), pp. 964-969
[25]
D.J. Holland, S.B. Prasad, T.H. Marwick.
Contribution of exercise echocardiography to the diagnosis of heart failure with preserved ejection fraction (HFpEF).
Heart., 96 (2010), pp. 1024-1028
[26]
Y.T. Tan, F. Wenzelburger, E. Lee, et al.
The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist and longitudinal motion.
J Am Coll Cardiol., 54 (2009), pp. 36-46
[27]
Y.T. Tan, F. Wenzelburger, E. Lee, et al.
Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction.
Heart., 96 (2010), pp. 1017-1023
[28]
M.R. Zile, W.H. Gaasch, I.S. Anand, et al.
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
Circulation., 121 (2010), pp. 1393-1405
[29]
M. Packer, P.A. Poole-Wilson, P.W. Armstrong, et al.
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure.
ATLAS Study Group. Circulation., 100 (1999), pp. 2312-2318
[30]
M.A. Konstam, J.D. Neaton, K. Dickstein, et al.
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
Lancet., 374 (2009), pp. 1840-1848
[31]
B. Pitt, F. Zannad, W.J. Remme, et al.
The effect of spironolac-tone on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators. N Engl J Med., 341 (1999), pp. 709-717
[32]
B. Pitt, W. Remme, F. Zannad.
etal. Eplerenone, a selective aldos-terone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med., 348 (2003), pp. 1309-1321
[33]
F. Zannad, J.J. McMurray, H. Krum, et al.
Eplerenone in patients with systolic heart failure and mild symptoms.
N Engl J Med., 364 (2011), pp. 11-21
[34]
D.N. Juurlink, M.M. Mamdani, D.S. Lee, et al.
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med., 351 (2004), pp. 543-551
[35]
B. Pitt, S.D. Anker, D.A. Bushinsky, et al.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Eur Heart J., 32 (2011), pp. 820-828
[36]
H.J. Levine.
Rest heart rate and life expectancy.
J Am Coll Cardiol., 30 (1997), pp. 1104-1106
[37]
J.K. Kjekshus.
Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials.
Am J Cardiol., 57 (1986), pp. 43F-49F
[38]
K. Swedberg, M. Komajda, M. Bohm, et al.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Lancet., 376 (2010), pp. 875-885
[39]
M. Bohm, K. Swedberg, M. Komajda, et al.
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Lancet., 376 (2010), pp. 886-894
[40]
Cullington D, Goode KM, Cleland JGF, et al. How many patients with chronic heart failure might be suitable for ivabradine? Heart, in press.
[41]
K.K. Witte, R. Desilva, S. Chattopadhyay, et al.
Are hematinic deficiencies the cause of anemia in chronic heart failure?.
Am Heart J., 147 (2004), pp. 924-930
[42]
D.O. Okonko, A. Grzeslo, T. Witkowski, et al.
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
J Am Coll Cardiol., 51 (2008), pp. 103-112
[43]
S.D. Anker, J. Comin Colet, G. Filippatos, et al.
Ferric carboxy-maltose in patients with heart failure and iron deficiency.
N Engl J Med., 361 (2009), pp. 2436-2448
[44]
P. van der Meer, H.F. Groenveld, J.L. Januzzi Jr., et al.
Ery-thropoietin treatment in patients with chronic heart failure: a meta-analysis.
Heart., 95 (2009), pp. 1309-1314
[45]
R.M. Beadle, M. Frenneaux.
Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease.
Heart., 96 (2010), pp. 824-830
[46]
L. Lee, R. Campbell, M. Scheuermann-Freestone, et al.
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Circulation., 112 (2005), pp. 3280-3288
[47]
Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011, doi:10.1136/hrt.2011.226332. Published online first: 23 June.
[48]
D. Gao, N. Ning, X. Niu, et al.
Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
Heart., 97 (2011), pp. 278-286
[49]
J.G. Cleland, J.C. Daubert, E. Erdmann, et al.
The effect of cardiac resynchronization on morbidity and mortality in heart failure.
N Engl J Med., 352 (2005), pp. 1539-1549
[50]
J.G. Cleland, M.J. Calvert, Y. Verboven, et al.
Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study.
Am Heart J., 157 (2009), pp. 457-466
[51]
J.G. Cleland, N. Freemantle, J.C. Daubert, et al.
Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study.
Heart., 94 (2008), pp. 278-283
[52]
A.J. Moss, W.J. Hall, D.S. Cannom, et al.
Cardiac-resynchronization therapy for the prevention of heart-failure events.
N Engl J Med., 361 (2009), pp. 1329-1338
[53]
A.S. Tang, G.A. Wells, M. Talajic, et al.
Cardiac-resynchronization therapy for mild-to-moderate heart failure.
N Engl J Med., 363 (2010), pp. 2385-2395
[54]
E.S. Chung, A.R. Leon, L. Tavazzi, et al.
Results of the predictors of response to CRT (PROSPECT) trial.
Circulation., 117 (2008), pp. 2608-2616
[55]
R.J. van Bommel, J. Gorcsan 3rd, E.S. Chung, et al.
Effects of cardiac resynchronisation therapy in patients with heart failure having a narrow QRS Complex enrolled in PROSPECT.
Heart., 96 (2010), pp. 1107-1113
[56]
P.W. Foley, K. Patel, N. Irwin, et al.
Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study.
Heart., 97 (2011), pp. 1041-1047
[57]
Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy. Meta-analysis of randomized controlled trials. Arch Intern Med. 2011, doi:10.1001/archinternmed.2011.247. Published online first: 20 June.
[58]
C. Lavalle, R.P. Ricci, M. Santini.
Atrial tachyarrhythmias and cardiac resynchronisation therapy: clinical and therapeutic implications.
Heart., 96 (2010), pp. 1174-1178
[59]
K. Dickstein, P.E. Vardas, A. Auricchio, et al.
2010 focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy.
Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J., 31 (2010), pp. 2677-2687
[60]
R.J. Shelton, A.L. Clark, K. Goode, et al.
A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure (CAFE-II Study).
Heart., 95 (2009), pp. 924-930
[61]
C.M. Yu, J.Y. Chan, Q. Zhang, et al.
Biventricular pacing in patients with bradycardia and normal ejection fraction.
N Engl J Med., 361 (2009), pp. 2123-2134
[62]
V.M. Conraads, P.J. Beckers.
Exercise training in heart failure: practical guidance.
Heart., 96 (2010), pp. 2025-2031
[63]
Rees K, Taylor RS, Singh S, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. 2004:CD003331.
[64]
C.M. O’Connor, D.J. Whellan, K.L. Lee, et al.
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
J Am Med Assoc., 301 (2009), pp. 1439-1450
[65]
K.E. Flynn, I.L. Pina, D.J. Whellan, et al.
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial.
J Am Med Assoc., 301 (2009), pp. 1451-1459
[66]
M.A. Spruit, R.M. Eterman, V.A. Hellwig, et al.
Effects of moderate-to-high intensity resistance training in patients with chronic heart failure.
Heart., 95 (2009), pp. 1399-1408
[67]
J. Kjekshus, E. Apetrei, V. Barrios, et al.
Rosuvastatin in older patients with systolic heart failure.
N Engl J Med., 357 (2007), pp. 2248-2261
[68]
V. Rizzello, D. Poldermans, E. Biagini, et al.
Prognosis of patients with ischaemic cardiomyopathy after coronary revascularisa-tion: relation to viability and improvement in left ventricular ejection fraction.
Heart., 95 (2009), pp. 1273-1277
[69]
J.G. Cleland, M. Calvert, N. Freemantle, et al.
The Heart Failure Revascularisation Trial (HEART).
Eur J Heart Fail., 13 (2011), pp. 227-233
[70]
E.J. Velazquez, K.L. Lee, M.A. Deja, et al.
Coronary artery bypass surgery in patients with left ventricular dysfunction.
N Engl J Med., 364 (2011), pp. 1607-1616
[71]
J.G. Cleland, N. Freemantle.
Revascularization for patients with heart failure.
Inconsistencies between theory and practice. Eur J Heart Fail., 13 (2011), pp. 694-697
[72]
Publication Committee for the VMAC Investigators (Vasodilata-tion in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. J Am Med Assoc. 2002; 287:1531-40.
[73]
C.M. O’Connor, R.C. Starling, A.F. Hernandez, et al.
Effect of nesiritide in patients with acute decompensated heart failure.
N Engl J Med., 365 (2011), pp. 32-43
[74]
B.M. Massie, C.M. O’Connor, M. Metra, et al.
Rolofylline, an adeno-sine A1-receptor antagonist, in acute heart failure.
N Engl J Med., 363 (2010), pp. 1419-1428
[75]
VoorsAA, H.C. Dittrich, B.M. Massie, et al.
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
J Am Coll Cardiol., 57 (2011), pp. 1899-1907
[76]
G.M. Felker, K.L. Lee, D.A. Bull, et al.
Diuretic strategies in patients with acute decompensated heart failure.
N Engl J Med., 364 (2011), pp. 797-805
Secondary publication: This article was published in its entirety, with the consent of the authors and editors, in Heart 2011; 97:1643-9.
Copyright © 2011. Sociedade Portuguesa de Cardiologia
